Ptc Therapeutics (PTCT) Equity Average (2013 - 2026)

Ptc Therapeutics' Equity Average history runs 14 years deep, the most recent figure standing at -$192.9 million for Q1 2026.

• In Q1 2026, Equity Average rose 69.95% year-over-year to -$192.9 million; the TTM figure through Mar 2026 stood at -$192.9 million (up 69.95% YoY), while the FY2025 annual figure was -$651.7 million, up 32.0% from the prior year.
• Equity Average was -$192.9 million for Q1 2026 at Ptc Therapeutics, down from -$180.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$44.6 million in Q1 2022 to a low of -$1.1 billion in Q4 2024.
• Historically, Equity Average has averaged -$484.8 million across 5 years, with a median of -$402.3 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Equity Average tumbled 802.65% in 2023, then jumped 83.22% in 2025.
• A 5-year view of Equity Average shows it stood at -$287.0 million in 2022, then sank by 159.48% to -$744.7 million in 2023, then slumped by 44.52% to -$1.1 billion in 2024, then surged by 83.22% to -$180.5 million in 2025, then decreased by 6.84% to -$192.9 million in 2026.
• The last three Equity Average figures came in at -$192.9 million (Q1 2026), -$180.5 million (Q4 2025), and -$181.2 million (Q3 2025), per Business Quant data.